Source: International Congress 2016 – Long-term oxygen therapy, noninvasive ventilation, and other clinical variables in chronic lung diseases
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Martina Šterclová (Prague, Czech Republic), Martina Sterclova, Martina Kolbekova, Magdalena Smetakova, Martina Vasakova. Markers of treatment outcome in hypersensitivity pneumonitis patients. Eur Respir J 2016; 48: Suppl. 60, 3706

Member's Comments

No comment yet.

Related content which might interest you: Bronchoalveolar lavage findings and disease progression in hypersensitivity pneumonitis Source: International Congress 2017 – ILDs: clinical aspects Year: 2017 Clinical and immunological parameters in patients with newly diagnosed sarcoidosis Source: Annual Congress 2013 –Diffuse parenchymal lung disease III Year: 2013 Impact of lymphocyte differential count in BALF on the mortality of patients with acute exacerbation of idiopathic chronic fibrosing interstitial pneumonia Source: International Congress 2016 – Clinical aspects of ILD Year: 2016 Bronchoalveolar lavage in patients with acute lung toxicity after chemo-radiotherapy for lung cancer Source: Eur Respir J 2003; 22: Suppl. 45, 29s Year: 2003 Comparative analysis of multiple gene polymorphisms for acute exacerbation of idiopathic pulmonary fibrosis Source: International Congress 2015 – IPF pathogenesis Year: 2015 Prognostic impact of bronchoalveolar lavage lymphocytosis in patients with chronic Hypersensitivity Pneumonitis Source: International Congress 2018 – CTD-ILD and hypersensitivity pneumonitis: risk stratification and management Year: 2018 Bronchoalveolar lavage findings in patients with diffuse interstitial lung disease (DILDs) Source: International Congress 2016 – Clinical aspects of ILD Year: 2016 The role of the combined assessment of the bronchoalveolar lavage (BAL) and radiological profile in the diagnosis of chronic eosinophilic pneumonia (CEP) Source: Annual Congress 2013 –Modern approach to various clinical settings Year: 2013 The value of lymphocytosis in bronchoalveolar lavage in the differential diagnosis between idiopathic pulmonary fibrosis and chronic hypersensitivity pneumonitis Source: Annual Congress 2011 - Work, the environment and respiratory disease Year: 2011 BAL neutrophilia increases mortality in lung transplant patients despite azithromycin treatment Source: Annual Congress 2013 –New insights into mechanisms of lung allograft dysfunction Year: 2013 Induced sputum and BAL from patients with hypersensitivity pneumonitis Source: Eur Respir J 2001; 18: Suppl. 33, 508s Year: 2001 Bronchoalveolar lavage Source: Eur Respir Mon; 2010: 48: 59–72 Year: 2010 Bronchoalveolar lavage for the evaluation of interstitial lung disease: is it clinically useful? Source: Eur Respir J 2011; 38: 761-769 Year: 2011 Ability of the lung clearance index to monitor progression of early lung disease in children with cystic fibrosis Source: International Congress 2016 – Cystic fibrosis: inflammation, microbiology, management and monitoring Year: 2016 Clinical significance of hemosiderin-laden macrophages in bronchoalveolar lavage fluid of patients with idiopathic interstitial pneumonias Source: Annual Congress 2013 –Diffuse pulmonary fibrosis Year: 2013 Proteological assesment of idiopathic pulmonary fibrosis and hypersensitivity pneumonitis by mean of broncho-alveolar lavage Source: Annual Congress 2011 - Bronchoalveolar lavage and biomarkers in diffuse parenchymal lung disease Year: 2011 Clinical features and outcomes of patients with diffuse alveolar hemorrhage during antithrombotic therapy Source: International Congress 2014 – ILDs 5 Year: 2014 Usefulness of anti-Ro52 antibodies in the BAL of the patients with ILDs. Pilot study Source: International Congress 2016 – ILD pathogenesis Year: 2016 Eosinophilic lung disease Source: International Congress 2016 – Orphan diseases I Year: 2016 Histopathological findings of biopsies from patients with extrinsic allergic alveolitis (hipersensitivity pneumonia) in subacute or chronic phase Source: Annual Congress 2013 –Diffuse parenchymal lung disease III Year: 2013